The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.
 
Maurice Perol
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sysmex
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Olivier Molinier
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
 
Alexis B. Cortot
No Relationships to Disclose
 
Jacques Margery
No Relationships to Disclose
 
Lionel Moreau
Travel, Accommodations, Expenses - Lilly
 
Virginie Westeel
No Relationships to Disclose
 
Pascal
No Relationships to Disclose
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Merck Serono; Novartis; Pfizer; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Roche/Genentech (Inst)
 
Eric Pichon
Speakers' Bureau - Bristol-Myers Squibb
 
Gerard Zalcman
No Relationships to Disclose
 
Patrick Dumont
No Relationships to Disclose
 
Nicolas Girard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Michel Poudenx
No Relationships to Disclose
 
Julien Mazieres
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
 
Jacques Cadranel
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer
 
Didier Debieuvre
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pierre Fabre; Roche
 
Jérôme Dauba
No Relationships to Disclose
 
Denis Moro-Sibilot
No Relationships to Disclose
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly/ImClone; PFIZER; Roche/Genentech
Research Funding - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; LILLY (Inst); Novartis; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - LILLY; PFIZER